Health and Healthcare
Mixed Short Interest in Drug & Medical Stocks (June 2007)
Published:
As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume. We ranked hese in terms of percentages with the largest increase in short interest first.
STOCK (Ticker) JUNE07 MAY07 Change
GlaxoSmithkline (GSK) 7.74M 4.15M +86%
Boston Scientific (BSX) 32.07M 24.06M +33.3%
Wyeth (WYE) 3.3M 10.37M +28.3%
Labcorp (LH) 4.11M 3.21M +28%
Bristol-Myers (BMY) 26.95M 23.85M +13%
Schering-Plough (SGP) 16.79M 15.27M +9.9%
Medtronic (MDT) 16.11M 15.19M +6%
Pfizer (PFE) 54.48M 52.12M +4.5%
Quest Diagnost. (DGX) 18.00M 17.54M +2.6%
Merck (MRK) 22.82M 22.55M +1.2%
Eli Lilly (LLY) 13.77M 14.07M -2.1%
J&J (JNJ) 15.37M 16.16M -4.9%
Zimmer Holdings (ZMH) 3.89M 4.13M -5.8%
St. Jude MEdical (STJ) 6.53M 7.13M -8.4%
Genentech (DNA) 6.87M 8.16M -15.9%
Abbott Labs (ABT) 11.74M 16.39M -28.3%
Jon C. Ogg
June 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
